Our January 2019 newsletter provides highlights from ARLG at IDWeek 2018^TM, held October 3rd-7th in San Francisco, CA. ARLG leaders, researchers, or committee members moderated panels and presented lectures, posters, or abstracts at close to 300 sessions.

In this issue, you can learn more about Sarah Doernberg, MD, MAS, of University of California, San Francisco who considers her role in the ARLG as a trialist in training. Dr. Doernberg has been involved in the development and execution of three protocols that each provide important contributions to the fight against antimicrobial resistance.

Check out our September 2018 newsletter for our latest fact sheets and lay summaries of results for the RADICAL and PROOF studies.

In this issue, we interview Yohei Doi, MD, PhD, chair of the Gram-negative Committee who provides his thoughts and insights on contributions to date and
future plans for this committee.

This issue also spotlights Ephraim Tsalik, MD, PhD, and his role as the principal investigator for the Rapid Diagnostics in Categorizing Acute Lung Infections (RADICAL) study.

The June 2018 newsletter features highlights from our Multi-Drug Resistance Organism (MDRO) global network meeting in Madrid, Spain, as well as an update from the ARLG Mentoring Program.

We also profile ARLG Research Fellow Judith Anesi, MD, and two Early Stage Investigator Grant recipients, Michael A. Liss, MD, MAS, FACS, and Jose M. Munita, MD. In addition to providing an update on their ARLG research, these award recipients discuss the impact of this funding to their careers and the benefits of the ARLG.

Our March 2018 newsletter shares updates from the 2018 ARLG Operations Retreat, as well as highlights the ARLG Special Populations Special Emphasis Panel and the Pediatrics Subcommittee.

You can also learn more about Ritu Banerjee, MD, PhD, who along with other ARLG investigators developed the Rapid Identification and Susceptibility Testing for Gram-Negative Bacteremia, (RAPIDS-GN). This study is evaluating antimicrobial utilization, clinical outcomes, and healthcare costs among patients with Gram-negative blood system infections using a diagnostic platform that rapidly detects organisms
and phenotypic drug resistance.